Intervention Protocol

Plasma exchange for multiple sclerosis

  1. Ilaria Casetta2,
  2. Gabriele Ciucci1,*,
  3. Ian Galea3

Editorial Group: Cochrane Multiple Sclerosis Group

Published Online: 14 APR 2010

Assessed as up-to-date: 14 MAR 2010

DOI: 10.1002/14651858.CD008480


How to Cite

Casetta I, Ciucci G, Galea I. Plasma exchange for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD008480. DOI: 10.1002/14651858.CD008480.

Author Information

  1. 1

    Ospedale S. Maria delle Croci, Divisione Neurologica, Ravenna, Italy

  2. 2

    Universita degli Studi di Ferrara, Sezione di Clinica Neurologica; Dip.to di Discipline Medico Chirurgiche della Comunicazione e del Comportamento, Ferrara, Italy

  3. 3

    University of Southampton, Division of Clinical Neurosciences, School of Medicine, Southampton, Hampshire, UK

*Gabriele Ciucci, Divisione Neurologica, Ospedale S. Maria delle Croci, Viale Randi, 5, Ravenna, 48100, Italy. g.ciucci@ausl.ra.it.

Publication History

  1. Publication Status: New
  2. Published Online: 14 APR 2010

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objective of this review is to evaluate the efficacy and safety of plasmapheresis (alone or in combination with other immunomodulating treatment) in patients with relapsing-remitting or secondary progressive or primary progressive MS.

We want to evaluate the principal hypothesis that plasmapheresis, performed during the relapses, can:
1. Improve disability after a relapse;
2. Reduce the number of relapses during the follow-up;
3. Prevent disability progression on long observation.

Moreover, we want to evaluate whether plasmapheresis performed during the progressive course can delay disability progression during the follow-up of patients with primary of secondary progressive MS.

The secondary aims are to evaluate if the effect of the treatment is different according to:
1. The type of course of MS;
2. The duration of the disease prior the beginning of the treatment with plasma exchange.